EVP R&D Exec Simrat Randhawa Buys 27,000 Shares While Dumping 30,000+ – Insider Confidence Amid 354% YTD Surge at DIANTHUS THERAPEUTICS

Insider Buying Surges While Selling Remains Steady

On June 1 2026, Randhawa Simrat, the EVP and Head of R&D, executed a Rule 10b5‑1 trading plan that saw her purchase nearly 27 000 shares of DIANTHUS THERAPEUTICS’ common stock at $8.44 to $22.07 each, bringing her post‑transaction holdings to 30 530 shares. The same day she also sold more than 30 000 shares at a weighted average of $89.72, reflecting a classic “buy‑sell” pattern that balances long‑term commitment with short‑term liquidity needs.

The buy‑side activity is noteworthy against a backdrop of a company that has delivered a staggering 353.90 % year‑to‑date gain, yet remains highly volatile with a 52‑week high of $96.50 and a current market cap of roughly $5 B. Simrat’s transactions are executed under a pre‑planned plan, suggesting confidence in the company’s pipeline of long‑acting monoclonal antibodies for autoimmune diseases, while the sales may be part of a cash‑flow strategy for her personal portfolio.

What It Means for Investors

• Signal of Insider Confidence – A large Rule 10b5‑1 purchase by a senior R&D executive is a positive signal that the insider believes the stock is undervalued, or at least has upside potential as the company advances its clinical programs.
• Liquidity Considerations – Simrat’s concurrent sales could temporarily dampen price momentum; however, the volume of shares sold is dwarfed by the buying, and the average sale price of $89.72 is well above the current trading price, indicating she is not dumping at a discount.
• Potential Catalyst – The company’s upcoming Phase III data on its flagship antibody could validate the insider’s confidence, creating a rally that would benefit those holding shares.

A Profile of Randhawa Simrat

Simrat has a long history of both option grants and share transactions, often executed under Rule 10b5‑1 plans. Her most recent series of purchases (150 000 shares in February 2026 and 60 000 in September 2025) shows a pattern of buying large blocks during periods of market volatility. She also sells large volumes when the stock reaches peak levels, as seen with the 33 830‑share sale in March 2026. Overall, her net equity position has steadily increased from 71 184 shares in March to 30 530 shares after the June transactions, reflecting a net accumulation of roughly 26 530 shares despite periodic selling. This accumulation trend aligns with her role overseeing drug development, suggesting she views the company’s long‑term prospects favorably.

Insider Activity in Context

When viewed alongside other executives—Savitz Ryan, the CFO, and Garcia Marino, the CEO—Simrat’s activity is among the most aggressive. While Ryan and Marino have mixed buying and selling, Simrat’s pattern shows a clear preference for accumulation. Her consistent use of Rule 10b5‑1 plans mitigates market timing concerns, reinforcing the idea that the purchases are driven by belief in the company’s future rather than short‑term speculation.

Bottom Line for Investors

• Positive Indicator – Simrat’s sizable buy‑side activity under a pre‑planned trading plan signals confidence in DIANTHUS THERAPEUTICS’ pipeline and future valuation.
• Short‑Term Volatility – The simultaneous sales may introduce temporary price pressure, but the overall net position remains long.
• Strategic Watch – Investors should monitor the upcoming clinical milestones and earnings reports, as these events are likely to unlock further upside that insiders are already positioned to benefit from.